Slingshot members are tracking this event:

Phase 3 data of Sarecycline, a once-daily, oral narrow-spectrum antibiotic with anti-inflammatory properties developed by Paratek (PRTK) in conjunction with Allergan (AGN) for Severe acne vulgaris due Q2 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
PRTK Community voting in process
AGN Community voting in process

Additional Information

Additional Relevant Details Paratek's second Phase 3 compound, sarecycline, a once-daily, oral narrow-spectrum antibiotic with anti-inflammatory properties, entered two identical Phase 3 registration studies for the treatment of moderate to severe acne vulgaris in December 2014 through its U.S. partner, Allergan. This program remains on track, with top-line data expected in 2016 and a potential new drug application in the U.S. in 2017. Paratek retains ex-U.S. rights to sarecycline.
Additional Relevant Details Update on 16 Feb 2017: This study has been completed.
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sarecycline, Severe Acne Vulgaris, Narrow-spectrum Antibiotic, Anti-inflammatory, Nda, Top-line Data, Phase 3